From Norway and Eurasia
Suven Life Sciences announced the grant of one (1) product patent from Eurasia (028038) and one (1) product patent from Norway (341252) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034 and 2026 respectively.The granted claims of the patents include the class of selective 5-HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
